(Q39815205)

14 September 2017

title

Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? (English)

1 reference

14 September 2017

1 reference

Mathis Grossmann

1

1 reference

14 September 2017

Jeffrey D Zajac

series ordinal

2

1 reference

14 September 2017

publication date

1 March 2011

1 reference

14 September 2017

published in

Clinical Endocrinology

1 reference

14 September 2017

volume

74

1 reference

14 September 2017

issue

3

1 reference

14 September 2017

page(s)

289-293

1 reference

Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Androgen deprivation therapy for prostate cancer: new concepts and concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Low testosterone levels are common and associated with insulin resistance in men with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Testosterone and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Cause of death in older men after the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Clinical practice. Osteoporosis in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Long-term effects of androgen deprivation therapy in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Quality of life three years after diagnosis of localised prostate cancer: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

Androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03939.X

10.1111/J.1365-2265.2010.03939.X

21 January 2018

Identifiers

DOI

1 reference

14 September 2017

1 reference